News

Number of news items returned: 21 to 40 records of 464

“Guarda Systems receives strong interest in products at World of Concrete Trade Show in the US”

30 January 2019

(2361 views)

  “Guarda Systems receives strong interest in products at World of Concrete Trade Show in the US” "Guarda Systems attended the World ...

"FREEDOM ROAD TRAVEL SECURE QUEENSLAND RUGBY UNION PARTNERSHIP"

28 January 2019

(2271 views)

  " FREEDOM ROAD TRAVEL SECURE QUEENSLAND RUGBY UNION PARTNERSHIP  Freedom Road Travel has gone from strength to strength in both the domestic ...

"Helio Lending in Hong Kong"

24 January 2019

(2425 views)

  "Helio Lending In Hong Kong   Helio Lending has been in attendance at the Asian Financial Forum in Hong Kong, represented by ...

Director Briefing with Dr Graeme Barnett from Qponics Limited

18 January 2019

(2727 views)

  In this Director Briefing, Dr Graeme Barnett, CEO and Managing Director of Qponics Limited ("Qponics", "the Company") discusses: Background of Qponics ...

Podcast: Delivering an Elite Business, Military Style (Ft. Scott Freeman of EMF, Elite Military Fitness)

20 December 2018

(2658 views)

  Podcast: Delivering an Elite Business, Military Style (Ft. Scott Freeman of EMF, Elite Military Fitness)   Today on Eden Exchanges we spoke ...

Guarda Releases Powerful Saw Dust Comparison Video

18 December 2018

(3752 views)

    Guarda Releases Powerful Saw Dust Comparison Video    "We are very excited that our brand new Guarda Edge Powercutter will be in ...

"EMF hires BlueMount Capital to assist with debt funding; potential exit in 3-5 years - co-owner"

18 December 2018

(2606 views)

    "EMF hires BlueMount Capital to assist with debt funding; potential exit in 3-5 years - co-owner"   "EMF Group of Companies, a ...

Qponics continues to upgrade pilot algae farm in Brisbane

12 December 2018

(3750 views)

  "Qponics continues to upgrade pilot algae farm in Brisbane The structural part of the new 65m x 12m raceway pond was ...

Podcast: Omega-3 Industry on The Rise With Algae Farming (ft. Dr Graeme Barnett, CEO & MD of Qponics)

12 December 2018

(4090 views)

  Podcast: Omega-3 Industry on The Rise With Algae Farming (ft. Dr Graeme Barnett, CEO & MD of Qponics) "Today on Eden ...

"Carhood launches AUD 1.5m pre-IPO round ahead of 2Q19 listing - new CEO"

07 December 2018

(3478 views)

  "Carhood launches AUD 1.5m pre-IPO round ahead of 2Q19 listing - new CEO"   "Carhood, a private Melbourne-based Australian car sharing rental ...

Helio Lending - Unlocking Cryptocurrency, Australian First Launches into Market

06 December 2018

(4121 views)

  "Unlocking Cryptocurrency, Australian First Launches into Market   Helio Lending today boldly launched into the Australian cryptocurrency market. Helio Lending is the ...

Edge Powercutter to be launched at upcoming World of Concrete Trade Show - Guarda

06 December 2018

(3592 views)

  Edge Powercutter to be launched at upcoming World of Concrete Trade Show - Guarda   "Guarda is excited to be launching the ...

Director Briefing with John O'Shea from Helio Lending Pty Ltd

03 December 2018

(3859 views)

  Please click on the link below to read the Director Briefing. For more information about Helio, please click here.

Readers, Birthday, Introductions & News - Funding Strategies Connect November 2018

30 November 2018

(3763 views)

  Readers, Birthday, Introductions & News - Funding Strategies Connect November 2018   Dear Readers, With the festive season fast approaching, I welcome you ...

Podcast: Unlocking The Value of Cryptocurrency (ft. John O'Shea, Founder of Helio Lending)

30 November 2018

(3846 views)

  Podcast: Unlocking The Value of Cryptocurrency (ft. John O'Shea, Founder of Helio Lending)   Eden Exchanges spoke to John O’Shea, Founder of ...

"Helio Lending working on USD 50m cryptocurrency listing on NYSE in 2019 - MD"

29 November 2018

(3977 views)

  "Helio Lending working on USD 50m cryptocurrency listing on NYSE in 2019 - MD"   "Helio Lending, a private Melbourne-based Australian cryptocurrency ...

Helio Lending partners with Crypto Tax Australia

28 November 2018

(4204 views)

  Helio Lending partners with Crypto Tax Australia   Helio Lending today announced an exciting partnership with Crypto Tax Australia, allowing cryptocurrency ...

"Integrative Healthcare set for AUD 15m (USD 11m) ASX listing in 2019, pre-IPO closing soon"

28 November 2018

(3937 views)

  "Integrative Healthcare set for AUD 15m (USD 11m) ASX listing in 2019, pre-IPO closing soon"   "Elevate Group, a Sydney, Australia-based integrated medical ...

"RE PRE IPO CAPITAL RAISING UPDATE - FURTHER $5M SECURED"

27 November 2018

(4115 views)

  "RE: PRE IPO CAPITAL RAISING UPDATE – FURTHER $5M SECURED Elevate Group provides person-centred healthcare through its clinics and the ...

Qponics begins upgrade to pilot algae farm in Brisbane

27 November 2018

(4093 views)

  "Qponics begins upgrade to pilot algae farm in Brisbane   Site preparation (image above) commenced on 26 November to upgrade the existing ...

JNCI publication involving CytImmune's CYT-21625

10 March 18

 

"JNCI publication involving CytImmune's CYT-21625"

 

"Please find attached [via the link below] an article published in the most recent version of the Journal of the National Cancer Institute (JNCI). This publication reports on a series of animal experiments comparing CytImmune's second generation nanomedicine, CYT-21625, against the commonly used chemotherapy, paclitaxel.


Key points:

1) CYT-21625 was safe with no toxicities observed.
2) The study involved three cancer models:
• Two thyroid cancers, traditional mouse xenograft models
• One Pancreatic neuroendocrine cancer, a genetically engineered mouse model.
3) Both anaplastic thyroid cancer (ATC) and pancreatic neuroendorine cancer (PNETs) are rare/orphan diseases, and have abysmal 5 year survival rates -- less than 5% for ATC and 16% for PNET patients with advanced disease.
4) CYT-21625 out-performed paclitaxel as measured by overall survival and using biological indicators that were specific to each cancer and model used.
We believe this study confirms the potential of the the Aurimune platform to deliver existing cancer drugs more effectively and with fewer toxic side effects. The paper concludes:

"CYT-21625 is effective in mice with PNETs [Pancreatic NeuroEndocrine Tumors] and metastatic human thyroid cancer with no toxicities. Thus, CYT-21625 should be studied in patients with advanced PNETs and thyroid cancer."

*Note that this study also used a CYT-6091 monotherapy as a control. As expected in this setting, while CYT-6091 showed some limited efficacy, it was inferior to therapies in which TNF is delivered in combination with chemotherapy. "

 

David Oarr, Chief Communications Officer, Project Karkinos, 10 March 2018.

Additional Documents

JNCI_CYT21625